PT3331495T - ¿sistema de distribuição de polímero líquido para administração prolongada de fármacos - Google Patents

¿sistema de distribuição de polímero líquido para administração prolongada de fármacos

Info

Publication number
PT3331495T
PT3331495T PT167514371T PT16751437T PT3331495T PT 3331495 T PT3331495 T PT 3331495T PT 167514371 T PT167514371 T PT 167514371T PT 16751437 T PT16751437 T PT 16751437T PT 3331495 T PT3331495 T PT 3331495T
Authority
PT
Portugal
Prior art keywords
drugs
delivery system
liquid polymer
polymer delivery
extended administration
Prior art date
Application number
PT167514371T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of PT3331495T publication Critical patent/PT3331495T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PT167514371T 2015-08-03 2016-08-03 ¿sistema de distribuição de polímero líquido para administração prolongada de fármacos PT3331495T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US201662275407P 2016-01-06 2016-01-06

Publications (1)

Publication Number Publication Date
PT3331495T true PT3331495T (pt) 2020-12-07

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167514371T PT3331495T (pt) 2015-08-03 2016-08-03 ¿sistema de distribuição de polímero líquido para administração prolongada de fármacos

Country Status (19)

Country Link
US (3) US10786515B2 (enExample)
EP (2) EP3804698B1 (enExample)
JP (1) JP6949820B2 (enExample)
KR (1) KR102696721B1 (enExample)
CN (1) CN107920988B (enExample)
AU (1) AU2016302252B2 (enExample)
BR (1) BR112018002414B1 (enExample)
CA (1) CA2994704A1 (enExample)
DK (1) DK3331495T3 (enExample)
EA (1) EA036951B1 (enExample)
ES (2) ES2836805T3 (enExample)
HR (1) HRP20201991T1 (enExample)
HU (1) HUE052832T2 (enExample)
IL (1) IL257221B (enExample)
MX (1) MX378264B (enExample)
PT (1) PT3331495T (enExample)
TW (1) TWI718168B (enExample)
WO (1) WO2017024027A1 (enExample)
ZA (1) ZA201800591B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2427383C2 (ru) 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
KR102696721B1 (ko) 2015-08-03 2024-08-19 톨마 인터내셔날 리미티드 약물의 장기간 지속적인 투여를 위한 액체 폴리머 전달 시스템
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
EP3856142A1 (en) 2018-09-25 2021-08-04 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
FI4302773T3 (fi) 2019-09-30 2024-12-09 Tolmar International Ltd Nestemäiset polymeerikoostumukset ja järjestelmät peptidien pitkäaikaiseen annosteluun vaikuttavina farmaseuttisina aineina
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
EP4221688A1 (en) 2020-09-30 2023-08-09 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
KR20240079177A (ko) * 2022-11-28 2024-06-04 동국제약 주식회사 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법
WO2024131788A1 (zh) * 2022-12-23 2024-06-27 长春金赛药业有限责任公司 一种GnRH拮抗剂可注射组合物及其制备方法和应用
WO2024168022A2 (en) * 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations
TW202432169A (zh) * 2023-02-10 2024-08-16 美商托馬股份有限公司 輔美康(degarelix)有機溶劑調配物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
EP1334990A1 (en) 2002-02-06 2003-08-13 Polyganics B.V. DL-Lactide-epsilon-caprolactone copolymers
CN101862455A (zh) 2003-06-26 2010-10-20 普西维达公司 原位胶凝的药物递送系统
US20090092650A1 (en) * 2004-12-15 2009-04-09 Warren Stephen L Sustained Delivery Formulations of Octreotide Compounds
AU2006236564B2 (en) 2005-04-15 2011-02-17 Besins Healthcare Luxembourg S.A.R.L. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20080247987A1 (en) 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof
US20070299043A1 (en) 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
RU2427383C2 (ru) * 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
US7740877B2 (en) 2006-04-07 2010-06-22 University Of Utah Research Foundation Aliphatically modified biodegradable block copolymers as thermogelling polymers
WO2009060473A2 (en) 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
CN102119022B (zh) 2008-08-12 2015-09-09 诺华股份有限公司 药物组合物
US8541360B2 (en) 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
EP2389413A1 (en) * 2009-01-23 2011-11-30 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
CN105663045A (zh) 2009-04-24 2016-06-15 伊休蒂卡有限公司 高体积分数的包封纳米颗粒的制备
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
DK2590629T3 (en) 2010-07-09 2015-01-12 Innocore Technologies B V Biodegradable PHASE SEPARATED, SEGMENTED MULTI block copolymers AND RELEASE OF BIOLOGICAL ACTIVE POLYPEPTIDES
WO2012060267A1 (ja) * 2010-11-04 2012-05-10 新日鐵化学株式会社 ハードコート層付ポリカーボネート
CN103384528B (zh) 2010-11-24 2016-04-13 杜雷科特公司 生物可降解的药物递送组合物
US20140309202A1 (en) 2010-11-30 2014-10-16 Lipocine Inc. High-strength testosterone undecanoate compositions
ES2820369T3 (es) 2011-03-31 2021-04-20 Ingell Tech Holding B V Composiciones biodegradables adecuadas para liberación controlada
BR112013031685B1 (pt) * 2011-06-10 2021-04-06 Icon Bioscience, Inc. Formulações de liberação prolongada para entrega de proteínas ao olho e métodos de preparar as mesmas
EP2768544A4 (en) * 2011-10-17 2015-06-24 Poly Med Inc ABSORBABLE IN SITU-MELAGING SYSTEM, METHOD OF MANUFACTURING THEREOF AND USE THEREOF
EP3137532B1 (en) 2014-05-01 2021-05-26 Ingell Technologies Holding B.V. Liquid triblock copolymer
KR101686986B1 (ko) 2014-07-28 2016-12-16 에스케이케미칼주식회사 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
KR102696721B1 (ko) 2015-08-03 2024-08-19 톨마 인터내셔날 리미티드 약물의 장기간 지속적인 투여를 위한 액체 폴리머 전달 시스템
US11752099B2 (en) 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents

Also Published As

Publication number Publication date
US10786515B2 (en) 2020-09-29
CN107920988B (zh) 2021-08-17
US20240066039A1 (en) 2024-02-29
AU2016302252A1 (en) 2018-02-22
US11779589B2 (en) 2023-10-10
CA2994704A1 (en) 2017-02-09
MX378264B (es) 2025-03-10
EA036951B1 (ru) 2021-01-19
ZA201800591B (en) 2021-07-28
EP3804698B1 (en) 2024-01-31
US12447158B2 (en) 2025-10-21
NZ739674A (en) 2024-10-25
TW201717960A (zh) 2017-06-01
KR102696721B1 (ko) 2024-08-19
HK1255638A1 (en) 2019-08-23
EP3331495B1 (en) 2020-11-04
HRP20201991T1 (hr) 2021-02-05
ES2836805T3 (es) 2021-06-28
IL257221A (en) 2018-03-29
BR112018002414B1 (pt) 2023-11-21
EP3804698A1 (en) 2021-04-14
JP6949820B2 (ja) 2021-10-13
AU2016302252B2 (en) 2022-01-20
IL257221B (en) 2022-01-01
BR112018002414A2 (pt) 2018-09-18
HUE052832T2 (hu) 2021-05-28
JP2018522906A (ja) 2018-08-16
KR20180030413A (ko) 2018-03-22
CN107920988A (zh) 2018-04-17
ES2975519T3 (es) 2024-07-08
EP3331495A1 (en) 2018-06-13
US20210060036A1 (en) 2021-03-04
WO2017024027A1 (en) 2017-02-09
EA201890436A1 (ru) 2018-09-28
MX2018001499A (es) 2018-08-01
TWI718168B (zh) 2021-02-11
US20180214459A1 (en) 2018-08-02
DK3331495T3 (da) 2020-12-14

Similar Documents

Publication Publication Date Title
ZA201800591B (en) Liquid polymer delivery system for extended administration of drugs
IL259735B (en) Systems and methods for controlled drug delivery pumps
IL255987B (en) Drug release device
IL250659A0 (en) Sensing systems for drug delivery devices
IL250660A0 (en) Skin sensors for drug delivery devices
EP3265064A4 (en) Drug delivery device
SG10202012083YA (en) Liquid delivery system
EP3260148A4 (en) Liquid drug administration device
EP3302265A4 (en) Drug delivery capsule
EP3275474A4 (en) Liquid medicine administration device
PT3310800T (pt) Sistemas de administração para a libertação controlada de fármacos
EP3263155A4 (en) Drug solution administering device
EP2968368A4 (en) CRANIAL DISTRIBUTION OF MEDICINAL PRODUCTS
HUE057487T2 (hu) Gyógyszeradagoló rendszer
IL246874A0 (en) drug delivery system
EP3351286A4 (en) DEVICE FOR THE ADMINISTRATION OF A MEDICAMENT SOLUTION
GB201419540D0 (en) Delivery of drugs
GB2551453B (en) Nanocarrier delivery system for hydrophobic substances
EP3319549A4 (en) ACTIVE RELEASE DEVICE
EP3258990A4 (en) Micro infusion device for drug delivery
EP3107532A4 (en) Transdermal drug delivery system containing donepezil
EP3380040A4 (en) PHARMACEUTICAL SYSTEM FOR DRUG DELIVERY
IL275664A (en) drug delivery system
EP3217947A4 (en) Kidney-targeted drug delivery systems
DK3484543T3 (da) Lægemiddelleveringssystem